- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06888687
Porovnání podpory dietetiky s a bez kontinuálního monitorování glukózy u jedinců s diabetem 2. typu. (CARE-T2D)
Neustálá dietetika e-health dietetics asistovaná monitorování glukózy, která posílí lidi s diabetem 2. typu
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via REDCap) have been collected, participants will be randomised into one of two groups (DIET, dietetic support only; CGMD, CGM plus dietetic support). All participants will receive four (4) dietetic consults via telehealth at weeks 2, 6, 10 and 16, the content of which will be related to the randomised condition. Measurements will be repeated at 3 and 6 months from baseline to assess the changes in primary and secondary outcomes.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Victoria
-
Melbourne, Victoria, Austrálie, 3065
- Australian Catholic University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Aged 18+ years
- Reside anywhere in Australia and have a postal address
- Confirmed T2D diagnosis by a GP/endocrinologist
- Current HbA1c of ≥7.0%
- Have a smartphone and able to independently use it
Exclusion Criteria:
- Under the age of 18 years
- Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids)
- Use of CGM within the last six months
- Eating Disorder Examination Questionnaire (EDE-Q) global score >2.8 OR global score > or equal to 1.52, with sum of Q14-18 > or equal to 4
- Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
- Not weight stable (>5 kg change over last three months)
- Severe hypoglycaemic event (i.e. requiring assistance) within last six months
- Change of antihyperglcyaemic medications within last three months
- Women who are pregnant or breastfeeding (within 24 weeks)
- History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
- History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Dietetic support only
This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
|
Experimentální: CGM plus dietetic support
The CGM plus dietetic support group will be provided 'standard care' dietetic support alongside the use, and interpretation of, the CGM data collected to assist in the understanding of dietary modifications on glucose management. As per the DIET group, dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. The CGM data collected via LibreLink will be used by both the participant and the dietitian to inform dietary modifications. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
HbA1c
Časové okno: baseline, 6 months
|
Glycated haemoglobin concentration |
baseline, 6 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
HbA1c
Časové okno: 3 months
|
Glycated haemoglobin concentration |
3 months
|
|
24 h assessment of glycaemia
Časové okno: baseline, 6 months
|
24 h glucose measures assessed by blinded CGM (including, but not limited to, time in range, CV) |
baseline, 6 months
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
CGM application and use
Časové okno: From 0 to 26 weeks, per 2 week period of sensor use
|
number of days of CGM use and interaction with viewing CGM data (via LibreLink); CGMD group ony |
From 0 to 26 weeks, per 2 week period of sensor use
|
|
Per protocol analysis
Časové okno: 6 months
|
Primary analysis of the primary outcome (0-6 months HbA1c) is going to be intention to treat. Therefore, secondary analysis of all other variables will be a per-protocol (PP) analysis. Inclusion in PP analysis will be defined by: 1. Attendance at ≥3 dietetic consults, within ±10 days of the designated 2-, 6-, 10- and 16-week time points. |
6 months
|
|
Dietary intake
Časové okno: baseline, 3 months, 6 months
|
energy and macronutrient composition calculated from food records |
baseline, 3 months, 6 months
|
|
Fasting blood glucose
Časové okno: baseline, 3 months, 6 months
|
fasting blood glucose concentrations |
baseline, 3 months, 6 months
|
|
Adherence
Časové okno: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
measures of adherence assessed by self-report (questionnaire) |
baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
|
hs-CRP
Časové okno: baseline, 3 months, 6 months
|
fasting high sensitive C-Peptide concentrations |
baseline, 3 months, 6 months
|
|
Fasting cholesterol
Časové okno: baseline, 3 months, 6 months
|
Fasting cholesterol concentrations (total, HDL and LDL) |
baseline, 3 months, 6 months
|
|
Fasting lipid concentration
Časové okno: baseline, 3 months, 6 months
|
fasting triglyceride concentrations |
baseline, 3 months, 6 months
|
|
Medication effect score (MES)
Časové okno: baseline, 6 months
|
Medication effect score for antihyperglycemic medications |
baseline, 6 months
|
|
Participant experience
Časové okno: 6 months
|
Qualitative semi-structured interviews |
6 months
|
|
Physical activity
Časové okno: baseline, 3 months, 6 months
|
Self-reported questionnaire (International Physical Activity Questionnaire (IPAQ) - Long Form) |
baseline, 3 months, 6 months
|
|
Sleep quality and quantity
Časové okno: baseline, 3 months, 6 months
|
Self-reported questionnaire (Pittsburgh Sleep Quality Index (PSQI)) |
baseline, 3 months, 6 months
|
|
Eating behaviours
Časové okno: baseline, 3 months, 6 months
|
Self-reported questionnaire (Eating Disorders Examination Questionnaire (EDEQ)) |
baseline, 3 months, 6 months
|
|
Health literacy
Časové okno: baseline, 3 months, 6 months
|
self-reported questionnaire (Health Literacy Questionnaire (HLQ)) |
baseline, 3 months, 6 months
|
|
Dietary quality
Časové okno: baseline, 3 months, 6 months
|
Assessed using the Healthy Eating Index For Australian adults (HEIFA) |
baseline, 3 months, 6 months
|
|
Diabetes self-management
Časové okno: baseline, 3 months, 6 months
|
Self-reported questionnaire (Diabetes Self-Management Questionnaire (DSMQ-R)) |
baseline, 3 months, 6 months
|
|
Diabetes distress
Časové okno: baseline, 3 months, 6 months
|
Self-reported questionnaire (Type 2 Diabetes Distress Assessment Scale (T2DDAS)) |
baseline, 3 months, 6 months
|
|
Overall well-being
Časové okno: baseline, 3 months, 6 months
|
Self-reported questionnaire (WHO-5) |
baseline, 3 months, 6 months
|
|
Diabetes-specific well-being
Časové okno: baseline, 3 months, 6 months
|
Self-reported questionnaire (DAWN Impact of Diabetes Profile (DIDP-7)) |
baseline, 3 months, 6 months
|
|
Treatment satisfaction
Časové okno: baseline, 3 months, 6 months
|
self-reported questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQs (status) and DTSQc (change))) |
baseline, 3 months, 6 months
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Onemocnění endokrinního systému
- Metabolické choroby
- Poruchy metabolismu glukózy
- Diabetes Mellitus
- Nutriční a metabolické nemoci
- Diabetes mellitus, typ 2
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Chemická analýza krve
- Testy klinické chemie
- Diagnostické techniky, endokrinní
- Monitorování, fyziologické
- Nepřetržité monitorování glukózy
Další identifikační čísla studie
- 2024-3690HC
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
Kritéria přístupu pro sdílení IPD
Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .